MedTrace Logo

Aricept to Improve Functional Tasks in Vascular Dementia

NCT00457769 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-02-17

No results posted yet for this study

Summary

Medications for memory improvement are available but they may not actually improve the ability to do real world tasks. The purpose of this research study is to determine if a medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember steps of functional tasks and the actual ability to perform tasks relevant to real-life independence. Aricept is an FDA approved medication for the treatment of Alzheimer's disease. Aricept is an investigational drug for the purposes of this study, and is not approved for this purpose.

Conditions

  • Stroke
  • Vascular Dementia
  • Memory Deficits

Interventions

DRUG

Donepezil and self-generated memory training

Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

DRUG

Donepezil and experimenter-administered memory training

Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Kessler Foundation

    lead OTHER

Principal Investigators

  • A. M. Barrett, MD · Kessler Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457769 on ClinicalTrials.gov